-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $52

Benzinga·07/23/2026 17:50:57
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $46 to $52.